New Kidney Drug Could Change Life for 800 Million Patients Worldwide

  • تاريخ النشر: منذ 7 ساعات زمن القراءة: دقيقة قراءة

Trial finds finerenone slows kidney decline and lowers complications in non-diabetic chronic kidney disease.

The Drug Is Finerenone

The Trial Included 1,584 Patients

Everyone Continued Standard Treatment

Kidney Function Declined More Slowly

Serious Complications Fell by 23%

Urinary Protein Dropped Sharply

Glomerular Diseases Also Responded

A Larger Analysis Strengthened the Evidence

High Potassium Remains an Important Risk

The 800 Million Figure Needs Context

  • 1 / 10
مقالات ذات صلة
Life in the UK Has Changed Dramatically Since 2000 — Here’s What May Surprise You
5 Signs of Kidney Stones… Don’t Ignore Them
GLP-1 Drugs Are Known for Weight Loss — But They Can Do More

A medicine already used for chronic kidney disease linked to type 2 diabetes has now shown broader benefits in people whose kidney disease is not caused by diabetes. The drug, finerenone, slowed kidney-function loss and reduced serious kidney and cardiovascular complications when added to standard treatment.

The finding comes from the international FIND-CKD trial, published in The New England Journal of Medicine in June 2026. Chronic kidney disease affects hundreds of millions worldwide, but the headline figure does not mean all 800 million patients can immediately receive finerenone. The trial focused on a specific high-risk group with non-diabetic chronic kidney disease and protein in their urine.

مواضيع ذات صلة